Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the United States, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market...
Website: bio-rad.com


  • Bad financial results growth rate -47.6% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (-11.9%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -2.8% (LTM)
  • Share price is 38.2% higher than minimum and 40.5% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (40.0x vs 21.4x)
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: BIO
Share price, USD:  (0.0%)299.28
year average price 275.96  


year start price 277.16 2025-02-14

min close price 216.56 2025-06-02

max close price 339.75 2025-10-24

current price 299.28 2026-02-13
Common stocks: 29 733 400

Dividend Yield:  0.0%
FCF Yield LTM: -2.8%
EV / LTM EBITDA: 40.0x
EV / Sales: 3.3x
Margin (EBITDA LTM / Revenue): 8.3%

Target EV / EBITDA (hist percentile): 21.4x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 8 899
Net Debt ($m): -338
EV (Enterprise Value): 8 561
EBITDA LTM (млн $): 214
EV / LTM EBITDA: 40.0x
Price to Book: 1.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-29globenewswire.com

BIO-key EMEA Subsidiary Partners with Citadel Global to Expand India Presence and Accelerate Adoption of Biometric Identity Solutions in Support of EU–India Free Trade Agreement

2026-01-28globenewswire.com

BIO-key and Visualforma Awarded Contract to Secure Digital Identities for Large Municipality in Portugal

2026-01-21seekingalpha.com

Artisan Mid Cap Value Fund Q4 2025 Performance Discussion And Portfolio Activity

2026-01-21zacks.com

Here's Why You Should Hold Bio-Rad Stock in Your Portfolio Now

2025-11-14globenewswire.com

Digital Identity and Biometric Access Management Provider BIO-key Reports Q3 Results; Highlights Enhanced Post Quarter Balance Sheet to Support 2026 Growth Goals; Holds Investor Call 10am ET Today

2025-11-12globenewswire.com

BIO-key Partners with VaporVM to Expand Reach of its Advanced Identity and Access Management and Biometric Cybersecurity Solutions in Middle East and Africa

2025-11-10globenewswire.com

BIO-key Showcases Biometric Identity Innovations at Africa Tech Festival 2025, November 10-13

2025-11-07globenewswire.com

BIO-key Secures Significant Identity and Biometric Security Deployment with a Major Middle East Defense Sector Organisation

2025-11-05prnewswire.com

BIO-TECHNE DECLARES DIVIDEND

2025-10-27globenewswire.com

BIO-key International and IT2Trust Partner to Strengthen IAM and Biometric Security Across the Nordic Region of Denmark, Sweden, Norway and Finland
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2023-10-27 2023-08-04 2023-05-05 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2025-02-14 16:30:41 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50 2022-02-11 16:35:56 2021-02-12 21:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 653M 652M 2 567M 650M 638M 611M 2 671M 632M 681M 677M 2 802M 681M 2 923M 2 546M
costOfRevenue 310M 306M 1 188M 294M 283M 284M 1 244M 296M 319M 314M 1 235M 307M 1 284M 1 108M
grossProfit 343M 345M 1 379M 356M 356M 326M 1 427M 336M 362M 362M 1 567M 374M 1 638M 1 438M
grossProfitRatio 0.526 0.53 0.548 0.557 0.534 0.531 0.532 0.535 0.549
researchAndDevelopmentExpenses 71M 61M 296M 91M 59M 64M 247M 44M 65M 75M 257M 70M 261M 218M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 207M 208M 814M 200M 196M 210M 842M 201M 208M 226M 828M 211M 877M 799M
otherExpenses 0 0 0 0 2M 700 000 0 20M 16M 50M 0 0 0 0
operatingExpenses 278M 268M 1 110M 291M 255M 274M 1 089M 245M 273M 301M 1 085M 281M 1 138M 1 017M
costAndExpenses 588M 575M 2 298M 585M 538M 559M 2 333M 541M 591M 615M 2 320M 588M 2 422M 2 124M
interestIncome 0 15M 82M 16M 17M 34M 101M 17M 17M 0 58M 8M 19M 18M
interestExpense 12M 13M 49M 12M 12M 12M 49M 12M 12M 12M 38M 12M 2M 22M
depreciationAndAmortization 34M 51M 152M 49M 47M 48M 146M 37M 36M 36M 177M 36M 138M 139M
ebitda -385M 477M -2 142M 923M -2 727M 100M -655M 149M 142M 148M -4 489M 129M 5 588M 5 078M
ebitdaratio -0.589 0.732 1.42 0.23 0.163 0.235 0.208 0.219 0.189
operatingIncome 65M 77M 269M 64M 100M 52M 338M 91M 90M 112M 483M 93M 500M 421M
operatingIncomeRatio 0.1 0.118 0.099 0.157 0.085 0.144 0.132 0.166 0.136
totalOtherIncomeExpensesNet -496M 337M -2 612M 797M -2 888M 439M -1 188M 59M -1 578M -28M -5 187M -302M 4 949M 4 497M
incomeBeforeTax -431M 414M -2 343M 862M -2 786M 491M -850M 137M -1 500M 85M -4 704M -209M 5 449M 4 918M
incomeBeforeTaxRatio -0.66 0.635 1.326 -4.364 0.804 0.217 -2.203 0.125 -0.307
incomeTaxExpense 89M 96M -498M 208M -621M 107M -213M 31M -338M 16M -1 077M -45M 1 195M 1 104M
netIncome -342M 318M -1 844M 653M -2 165M 384M -637M 106M -1 162M 69M -3 628M -164M 4 254M 3 814M
netIncomeRatio -0.524 0.488 1.005 -3.392 0.629 0.168 -1.706 0.102 -0.241
eps -12.7 11.67 -65.36 23.37 -76.26 13.46 -21.82 3.65 -39.59 2.33 -121.79 -5.52 142.61 127.86
epsdiluted -12.7 11.67 23.34 -76.26 13.45 3.64 -39.59 2.32 -5.52
weightedAverageShsOut 27M 27M 28M 28M 28M 29M 29M 29M 29M 30M 30M 30M 30M 30M
weightedAverageShsOutDil 27M 27M 28M 28M 28M 29M 29M 29M 29M 30M 30M 30M 30M 30M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-17 2022-02-11 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 33M 51M 20M 17M -4M
ebit -2 294M -801M -4 666M 5 451M 4 940M
nonOperatingIncomeExcludingInterest 2 563M 1 138M 5 149M -4 950M -4 519M
netIncomeFromContinuingOperations -1 844M -637M -3 628M 4 254M 3 814M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -1 844M -637M -3 628M 4 254M 3 814M
epsDiluted -65.36 -21.82 -121.79 140.83 126.2

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2023-10-27 2023-08-04 2023-05-05 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2025-02-14 16:30:41 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50 2022-02-11 16:35:56 2021-02-12 21:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 398M 369M 488M 412M 407M 433M 404M 458M 390M 464M 434M 518M 471M 662M
shortTermInvestments 1 023M 1 005M 1 176M 1 212M 1 215M 1 218M 1 203M 1 307M 1 338M 1 393M 1 356M 1 338M 399M 329M
cashAndShortTermInvestments 1 421M 1 374M 1 665M 1 622M 1 622M 1 651M 1 607M 1 765M 1 728M 1 857M 1 791M 1 856M 870M 991M
netReceivables 474M 470M 453M 462M 455M 460M 489M 457M 492M 498M 495M 432M 424M 419M
inventory 783M 799M 760M 804M 804M 783M 781M 776M 777M 753M 719M 686M 572M 622M
otherCurrentAssets 164M 169M 31M 167M 175M 167M 32M 149M 142M 169M 29M 166M 16M 16M
totalCurrentAssets 2 842M 2 811M 3 030M 3 056M 3 056M 3 061M 3 048M 3 147M 3 139M 3 277M 3 158M 3 140M 1 990M 2 140M
propertyPlantEquipmentNet 0 740M 689M 719M 715M 711M 724M 711M 688M 681M 680M 633M 716M 694M
goodwill 579M 582M 411M 415M 412M 413M 414M 407M 412M 408M 407M 400M 347M 292M
intangibleAssets 388M 397M 294M 307M 307M 314M 321M 314M 329M 328M 332M 325M 254M 200M
goodwillAndIntangibleAssets 967M 979M 704M 722M 719M 726M 734M 721M 740M 736M 739M 725M 601M 491M
longTermInvestments 5 058M 5 577M 4 839M 6 003M 5 100M 8 019M 7 698M 7 218M 7 311M 8 879M 8 831M 7 459M 14 387M 9 561M
taxAssets 0 0 0 0 878M 1 541M 0 1 370M 1 402M 1 769 781M 0 0 0 0
otherNonCurrentAssets 829M 108M 102M 104M -781M -1 449M 95M -1 271M -1 302M -1 769 685M 95M 102M 104M 87M
totalNonCurrentAssets 6 854M 7 403M 6 334M 7 548M 6 632M 9 549M 9 251M 8 749M 8 839M 10 390M 10 344M 8 918M 15 809M 10 833M
otherAssets 0 0 0 25 000 0 0 0 0 0 0 47 000 0 82 000 13 000
totalAssets 9 696M 10 214M 9 364M 10 603M 9 688M 12 610M 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M 17 799M 12 973M
accountPayables 129M 139M 122M 122M 127M 103M 145M 267M 304M 335M 135M 335M 142M 139M
shortTermDebt 38M 41M 1M 43M 42M 41M 500 000 476 000 476 000 519 000 465 000 448 000 489 000 1M
taxPayables 45M 36M 31M 44M 36M 34M 36M 104M 74M 51M 32M 29M 46M 57M
deferredRevenue 0 0 0 0 -127M 34M 0 -112M 74M 0 52M 1 484 606M 51M 42M
otherCurrentLiabilities 311M 333M 147M 289M 282M 289M 162M 403M 203M 254M 117M -1 484 371M 128M 131M
totalCurrentLiabilities 522M 549M 468M 498M 487M 466M 523M 558M 582M 590M 569M 571M 681M 632M
longTermDebt 1 357M 1 366M 1 200M 1 344M 1 351M 1 190M 1 199M 1 199M 1 198M 1 198M 1 198M 1 197M 11M 1M
deferredRevenueNonCurrent 0 0 0 -38 000 160M 169M 0 -1 370M -1 402M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 873M 961M 818M 1 076M 878M 1 541M 1 476M 1 370M 1 402M 1 770M 1 770M 1 485M 3 065M 2 077M
otherNonCurrentLiabilities 208M 210M 177M 198M 194M 192M 195M 1 723M 1 751M 346M 196M -1 481 907M 182M 197M
totalNonCurrentLiabilities 2 437M 2 537M 2 327M 2 618M 2 423M 3 093M 3 035M 2 922M 2 949M 3 314M 3 318M 3 034M 3 433M 2 461M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 165M 204M 173M 187M 202M 169M 206M 167M 147M 183M 190M 192M 212M 223M
totalLiabilities 2 960M 3 085M 2 795M 3 116M 2 910M 3 559M 3 558M 3 480M 3 531M 3 904M 3 886M 3 605M 4 114M 3 093M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 3000 3000 3000 0 3000 3000 3000 3000 3000 3000 3000
retainedEarnings 7 456M 7 798M 7 416M 8 132M 7 479M 9 645M 9 261M 8 911M 8 805M 9 967M 9 898M 9 047M 13 525M 9 268M
accumulatedOtherComprehensiveIncomeLoss -167M -154M -538M -315M -451M -426M -336M -498M -373M -408M -467M -845M -176M 282M
othertotalStockholdersEquity -553M -515M -329M -249M -167M 3M 15M 205M 252M
totalStockholdersEquity 6 737M 7 129M 6 569M 7 488M 6 779M 9 051M 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M 13 685M 9 880M
totalEquity 6 737M 7 129M 6 569M 7 488M 6 779M 9 051M 8 741M 8 416M 8 447M 9 764M 9 615M 8 454M 13 685M 9 880M
totalLiabilitiesAndStockholdersEquity 9 696M 10 214M 10 603M 9 688M 12 610M 11 896M 11 978M 13 667M 12 058M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9 696M 10 214M 9 364M 10 603M 9 688M 12 610M 12 299M 11 896M 11 978M 13 667M 13 502M 12 058M 17 799M 12 973M
totalInvestments 6 081M 6 581M 6 016M 7 215M 6 315M 9 237M 8 901M 8 525M 8 649M 10 271M 10 187M 8 797M 14 786M 9 890M
totalDebt 1 395M 1 407M 1 375M 1 388M 1 393M 1 400M 1 406M 1 199M 1 199M 1 199M 1 388M 1 198M 223M 226M
netDebt 998M 1 037M 887M 978M 985M 966M 1 002M 741M 809M 734M 954M 680M -247M -436M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-17 2022-02-11 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 453M 489M 495M 424M 419M
otherReceivables 0 0 0 0 0
prepaids 123M 140M 124M 109M 91M
totalPayables 154M 180M 167M 188M 197M
otherPayables 31M 36M 32M 46M 57M
accruedExpenses 124M 140M 195M 277M 223M
capitalLeaseObligationsCurrent 42M 40M 36M 36M 37M
capitalLeaseObligationsNonCurrent 131M 166M 154M 176M 186M
treasuryStock -772M -633M -264M -106M -100M
additionalPaidInCapital 463M 449M 447M 442M 429M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO BIO
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208 12 208
fillingDate 2025-10-29 2025-07-31 2024-10-31 2024-08-02 2024-05-08 2023-10-27 2023-08-04 2023-05-05 2022-10-28
acceptedDate 2025-10-29 16:18:31 2025-07-31 16:17:43 2025-02-14 16:30:41 2024-10-31 16:14:35 2024-08-02 16:15:19 2024-05-08 16:31:24 2024-02-16 16:31:26 2023-10-27 16:31:15 2023-08-04 16:31:06 2023-05-05 16:31:07 2023-02-17 17:07:55 2022-10-28 17:13:50 2022-02-11 16:35:56 2021-02-12 21:00:53
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -342M -120M -1 844M 653M -2 165M 384M -637M 106M -1 162M 69M -3 628M -164M 4 254M 3 814M
depreciationAndAmortization 54M -38M 152M 49M 47M 48M 146M 37M 36M 36M 137M 33M 138M 139M
deferredIncomeTax -88M 0 0 167M -659M 84M 0 -16M -13M -13 900 0 0 0 0
stockBasedCompensation 0 -15M 62M -30M 15M 15M 61M 16M 13M 17M 61M 16M 51M 42M
changeInWorkingCapital -14M -44M -621M 221M -24M -28M -433M 360M -16M -39M -1 610M -100M 1 143M 1 089M
accountsReceivables 4M -37M 16M -33M -4M 37M 11M 26M 7M -1M -87M 1M -20M -15M
inventory 14M 18M 9M 31M -22M -9M -46M -6M -25M -30M -159M -48M 46M -52M
accountsPayables -33M -30M -41M 27M 18M -44M -52M -38M -43M 8M -94M -27M 70M 125M
otherWorkingCapital 1M 6M -605M 196M -15M -13M -346M 378M 45M -16M -1 270M -27M 1 048M 1 031M
otherNonCashItems 511M 334M 2 706M -896M 3 002M -307M 1 238M -406M 1 241M 16M 5 234M 224M -4 917M -4 498M
netCashProvidedByOperatingActivities 121M 117M 455M 164M 98M 69M 375M 98M 98M 98M 194M 8M 669M 585M
investmentsInPropertyPlantAndEquipment -32M -46M -166M -40M -42M -40M -157M -44M -35M -36M -113M -24M -134M -109M
acquisitionsNet 0 -217M 0 0 66 000 26 000 3M 44M 35M 36M -99M -101M -126M -84M
purchasesOfInvestments -224M -153M -1 277M -399M -248M -406M -689M -196M -138M -204M -2 060M -329M -852M -248M
salesMaturitiesOfInvestments 214M 300M 1 305M 407M 259M 404M 863M 231M 201M 169M 1 066M 369M 767M 368M
otherInvestingActivites -2M 0 -23M 11M 26 000 -44M -35M -36M 6000
netCashUsedForInvestingActivites -43M -115M -56M -31M -43M -10M 28M -70M -85M
debtRepayment -300 000 -200 000 -123 000 -118 000 -118 000 -118 000 -116 000 -115 000 -113 000
commonStockIssued 3M 4M 0 0 6M 5M 0 0 0
commonStockRepurchased -53M -140M -204M -98M -101M -5M -429M -21M 0 0 -216M -129M -50M -100M
dividendsPaid 0 0 -16M 0 -16M 0 0 -14 662M -30M
otherFinancingActivites -2M -100 000 18M 5M -617 000 -5M -203M 14 666M 151M
netCashUsedProvidedByFinancingActivities -53M -136M -96M -97M 638 000 -27M -203M 4M -9M
effectOfForexChangesOnCash 1M -16M 9M -8M 4M 3M 321 000 6M 3M -2M 3M 8M -13M 12M
netChangeInCash 27M -151M 85M 5M -26M 29M -30M 68M -74M 30M -37M -79M -196M 4M
cashAtEndOfPeriod 398M 372M 490M 412M 407M 433M 404M 458M 390M 465M 435M 518M 471M 667M
cashAtBeginningOfPeriod 372M 523M 404M 407M 433M 404M 435M 390M 465M 435M 471M 597M 667M 663M
operatingCashFlow 121M 117M 455M 164M 98M 69M 375M 98M 98M 98M 194M 8M 669M 585M
capitalExpenditure -32M -46M -189M -64M -42M -40M -157M -44M -35M -36M -114M -24M -134M -109M
freeCashFlow 89M 71M 266M 100M 55M 29M 218M 54M 63M 62M 80M -17M 536M 476M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-14 2024-02-16 2023-02-17 2022-02-11 2021-02-16
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -23M 211 000 -1M -453M 3M
netCashProvidedByInvestingActivities -160M 20M -1 208M -797M -70M
netDebtIssuance -400 000 -467 000 1 186M -3M -427M
longTermNetDebtIssuance -400 000 -467 000 1 186M -3M -427M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -204M -429M -216M -50M -100M
netCommonStockIssuance -204M -429M -216M -50M -100M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -15M 4M 4M -2M 4M
netCashProvidedByFinancingActivities -219M -426M 974M -55M -523M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-31 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-13 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-15 ET (fiscal 2023 q4)
2023 q3
2023-10-26 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-16 ET (fiscal 2022 q4)
2022 q3
2022-10-27 ET (fiscal 2022 q3)
2022 q2
2022-07-28 ET (fiscal 2022 q2)
2022 q1
2022-04-28 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2026-02-12 16:16 ET
Bio-Rad Laboratories published news for 2025 q4
SEC form 8
2026-02-12 16:16 ET
Bio-Rad Laboratories reported for 2025 q4
SEC form 8
2026-02-12 16:16 ET
Bio-Rad Laboratories published news for 2025 q4
SEC form 10
2025-10-29 20:18 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories reported for 2025 q3
SEC form 8
2025-10-29 20:16 ET
Bio-Rad Laboratories published news for 2025 q3
SEC form 10
2025-07-31 20:17 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories reported for 2025 q2
SEC form 8
2025-07-31 20:15 ET
Bio-Rad Laboratories published news for 2025 q2
SEC form 10
2025-05-01 20:30 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 8
2025-05-01 20:20 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 8
2025-05-01 20:20 ET
Bio-Rad Laboratories reported for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Bio-Rad Laboratories published news for 2025 q1
SEC form 10
2025-02-14 16:30 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 10
2025-02-14 00:00 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories reported for 2024 q4
SEC form 8
2025-02-13 16:28 ET
Bio-Rad Laboratories published news for 2024 q4
SEC form 10
2024-10-31 16:14 ET
Bio-Rad Laboratories reported for 2024 q3
SEC form 8
2024-10-30 16:17 ET
Bio-Rad Laboratories published news for 2024 q3
SEC form 8
2024-10-30 16:17 ET
Bio-Rad Laboratories published news for 2024 q3
SEC form 10
2024-08-02 16:15 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 10
2024-08-02 00:00 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 8
2024-08-01 16:18 ET
Bio-Rad Laboratories published news for 2024 q2
SEC form 8
2024-08-01 16:18 ET
Bio-Rad Laboratories reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Bio-Rad Laboratories published news for 2024 q1
SEC form 8
2024-05-07 16:18 ET
Bio-Rad Laboratories reported for 2024 q1
SEC form 8
2024-05-07 16:18 ET
Bio-Rad Laboratories published news for 2024 q1
SEC form 10
2024-02-16 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories published news for 2023 q4
SEC form 8
2024-02-15 00:00 ET
Bio-Rad Laboratories reported for 2023 q4
SEC form 10
2023-10-27 16:31 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 10
2023-10-27 00:00 ET
Bio-Rad Laboratories published news for 2023 q3
SEC form 8
2023-10-26 16:17 ET
Bio-Rad Laboratories reported for 2023 q3
SEC form 10
2023-08-04 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-08-03 16:19 ET
Bio-Rad Laboratories reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-07-20 16:31 ET
Bio-Rad Laboratories published news for 2023 q2
SEC form 6
2023-06-05 08:45 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Bio-Rad Laboratories published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Bio-Rad Laboratories reported for 2023 q1
SEC form 10
2023-02-17 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 8
2023-02-16 00:00 ET
Bio-Rad Laboratories reported for 2022 q4
SEC form 10
2022-10-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 8
2022-10-27 00:00 ET
Bio-Rad Laboratories reported for 2022 q3
SEC form 10
2022-07-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 8
2022-07-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 8
2022-04-28 00:00 ET
Bio-Rad Laboratories reported for 2022 q1
SEC form 10
2022-02-11 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 8
2022-02-10 00:00 ET
Bio-Rad Laboratories published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Bio-Rad Laboratories published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
Bio-Rad Laboratories published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
Bio-Rad Laboratories published news for 2021 q1